Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children

This publication has 17 references indexed in Scilit:

• Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster
  European Journal of Clinical Microbiology & Infectious Diseases, 1994
• Immunogenicity of the Recombinant GenHevac B Pasteur Vaccine against Hepatitis B in Chronic Uremic Patients
  The Journal of Infectious Diseases, 1994
• Immunogenicity of recombinant hepatitis B vaccine in urban black children from Ga-Rankuwa, Bophuthatswana, South Africa
  The Pediatric Infectious Disease Journal, 1992
• Improved immunogenicity in mice of a recombinant hepatitis B vaccine containing preS1 and preS2 antigens in HBs particles
  Journal of Hepatology, 1991
• Protective potential of hepatitis B virus antigens other than the S gene protein
  Vaccine, 1990
• Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine
  Vaccine, 1990
• Immunological Response to Pre-S Antigens of the Hepatitis B Virus
  Viral Immunology, 1987
• Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus
  Cell, 1986
• HEPATITIS B VACCINATION: HOW LONG DOES PROTECTION LAST?
  The Lancet, 1984
• Biophysical and biochemical properties of purified preparations of hepatitis B surface antigen (HBS Ag)
  The Lancet Healthy Longevity, 1975